AU2006245916B2 - Erythropoietin variants - Google Patents

Erythropoietin variants Download PDF

Info

Publication number
AU2006245916B2
AU2006245916B2 AU2006245916A AU2006245916A AU2006245916B2 AU 2006245916 B2 AU2006245916 B2 AU 2006245916B2 AU 2006245916 A AU2006245916 A AU 2006245916A AU 2006245916 A AU2006245916 A AU 2006245916A AU 2006245916 B2 AU2006245916 B2 AU 2006245916B2
Authority
AU
Australia
Prior art keywords
polynucleotide
epo
polypeptide
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006245916A
Other languages
English (en)
Other versions
AU2006245916A1 (en
Inventor
Christel Bonnas
Ulrich Dirnagl
Andreas Meisel
Josef Priller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin filed Critical Charite Universitaetsmedizin Berlin
Publication of AU2006245916A1 publication Critical patent/AU2006245916A1/en
Application granted granted Critical
Publication of AU2006245916B2 publication Critical patent/AU2006245916B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006245916A 2005-05-13 2006-05-15 Erythropoietin variants Ceased AU2006245916B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants
EP05010473.6 2005-05-13
PCT/EP2006/004564 WO2006120030A1 (en) 2005-05-13 2006-05-15 Erythropoietin variants

Publications (2)

Publication Number Publication Date
AU2006245916A1 AU2006245916A1 (en) 2006-11-16
AU2006245916B2 true AU2006245916B2 (en) 2012-03-15

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006245916A Ceased AU2006245916B2 (en) 2005-05-13 2006-05-15 Erythropoietin variants

Country Status (12)

Country Link
EP (2) EP1736481A1 (OSRAM)
JP (1) JP5231214B2 (OSRAM)
KR (1) KR101468737B1 (OSRAM)
CN (1) CN101175768B (OSRAM)
AU (1) AU2006245916B2 (OSRAM)
BR (1) BRPI0608769A2 (OSRAM)
CA (1) CA2608379C (OSRAM)
DK (1) DK1885747T3 (OSRAM)
ES (1) ES2457398T3 (OSRAM)
RU (1) RU2430162C2 (OSRAM)
WO (1) WO2006120030A1 (OSRAM)
ZA (1) ZA200709091B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339613B (es) 2005-08-05 2016-06-02 Araim Pharmaceuticals Inc Peptidos protectores de tejido y sus usos.
WO2008137636A2 (en) * 2007-05-02 2008-11-13 University Of Utah Research Foundation Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
NZ601868A (en) 2008-01-22 2014-05-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
KR102233664B1 (ko) 2012-12-05 2021-04-02 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
EP3456817B1 (en) 2013-02-06 2025-07-09 Nc Medical Research Inc. Heterogeneous subpopulation of bone marrow cells for use in the treatment of neurodegeneration caused by ischemic stroke
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US11117942B2 (en) 2015-08-31 2021-09-14 The Trustees Of The University Of Pennsylvania AAV-EPO for treating companion animals
EP3587443A4 (en) * 2017-02-27 2021-02-17 Sylus Co., Ltd. USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
EP3916008A1 (en) * 2020-05-26 2021-12-01 Sylus Co., Ltd. New peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
EP4355425A1 (en) * 2021-06-15 2024-04-24 Andremacon S.r.l. Epo variants and modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
GB2413328A (en) * 2004-04-23 2005-10-26 Cambridge Antibody Tech Erythropoietin protein variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Also Published As

Publication number Publication date
KR20080021595A (ko) 2008-03-07
RU2430162C2 (ru) 2011-09-27
CA2608379A1 (en) 2006-11-16
AU2006245916A1 (en) 2006-11-16
JP2008539745A (ja) 2008-11-20
EP1736481A1 (en) 2006-12-27
EP1885747B1 (en) 2013-11-20
JP5231214B2 (ja) 2013-07-10
EP1885747A1 (en) 2008-02-13
ZA200709091B (en) 2009-08-26
BRPI0608769A2 (pt) 2010-01-26
CA2608379C (en) 2014-12-16
RU2007146455A (ru) 2009-06-20
CN101175768A (zh) 2008-05-07
DK1885747T3 (en) 2014-02-24
KR101468737B1 (ko) 2014-12-09
CN101175768B (zh) 2013-09-11
WO2006120030A8 (en) 2006-12-28
ES2457398T3 (es) 2014-04-25
WO2006120030A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
KR101468737B1 (ko) 에리트로포이에틴 변이체
US20190106470A1 (en) Erythropoietin variants
US7893240B2 (en) High level expression of recombinant human erythropoietin having a modified 5′-UTR
DE60223511T2 (de) Neurotrophe faktoren
JP6663428B2 (ja) Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
IL191426A (en) Erythropoietin polypeptides, their preparation and uses thereof
EP2081956B1 (en) Method of cell culture and method of treatment comprising a vepo protein variant
JPH10508756A (ja) 造血タンパク質を用いて赤血球形成を刺激する方法
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
US6835381B1 (en) Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
CA2583243A1 (en) Promotion of cell migration and axon regeneration in the cns
US20030211991A1 (en) Human sez6 nucleic acids and polypeptides
KR101330033B1 (ko) 인간 과립구 콜로니 자극 인자(ｇ-ｃｓｆ)의 변이체를 포함하는 허혈성 질환 치료용 약학 조성물
EP1373500B1 (en) Gene involved in v(d)j recombination and/or dna repair
US8748568B2 (en) Isolated A-type FHF N-terminal domain peptides and methods of use
EP1192181B1 (en) Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor
JP2003532623A (ja) 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法
JP2003128575A (ja) 脳腫瘍治療剤
JPWO1999055864A1 (ja) 新規なポリペプチド、そのポリペプチドをコードするｃＤＮＡ、およびその用途
JPWO1999055863A1 (ja) 新規なポリペプチド、そのポリペプチドをコードするｃＤＮＡ、およびその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired